Quitting Smoking: Ending the Penalty for Vulnerable Patients

Money should not be an obstacle to quitting smoking, especially when it comes to preventing serious complications or avoidable recurrences. In practice, however, current reimbursement rules expose the most vulnerable patients to a ‘double penalty’: persistent addiction due to lack of financial resources and serious consequences for their health that will put lasting pressure on their health and on the healthcare system.

Dr. Pierre Nys, a general practitioner since 1993 and a tobacco expert for 15 years, provides consultations on tobacco addiction. His conclusion is indisputable. “Tobacco to roll yourself is not expensive. A month of nicotine replacement, on the other hand, costs 50 euros,” he remembers. An amount that represents an insurmountable obstacle for many patients in a precarious situation – including pregnant women and patients with psychiatric disorders, chronic conditions or complex social situations. In these circumstances, motivation is no longer sufficient: quitting becomes materially unfeasible, despite the existence of certain one-off support measures.

This financial barrier undermines the entire logic of prevention. “We ask patients who are already struggling to make an enormous effort, without giving them the concrete means to achieve this,” the GP summarizes. The paradox is all the more striking because medium-term withdrawal failure leads to expensive medical complications: worsening of comorbidities, repeated hospital admissions, loss of quality of life. “We could help earlier, prevent many situations, and that would cost the system less,” he emphasizes.

The administrative absurdity of bupropion
In addition to nicotine replacement, access to drug treatments illustrates a major administrative inconsistency. Bupropion is the most striking example of this. This medicine is reimbursed when prescribed as an antidepressant, but its use to support smoking cessation is strictly regulated.

“To prescribe bupropion in the context of reimbursed support for quitting smoking, the patient must have COPD grade 2, have consulted a pulmonologist, have undergone spirometry… “, explains Dr. Nys. A cumbersome procedure that is difficult to reconcile with the reality of general medicine, especially given the waiting times for a specialized consultation, which sometimes last for months, with no guarantee that the legal criteria for reimbursement will ultimately be met.

In practice, some doctors are forced to adjust antidepressant treatment – for example by replacing an SSRI such as escitalopram with bupropion – to remain within the legal framework for reimbursement. “That is an administrative burden that is completely pointless from a public health perspective,” the tobacco expert concludes.

Integrate tobacco withdrawal into care pathways
To overcome this impasse, Dr. Nys advocates a structural change: no longer treating tobacco withdrawal as an isolated problem, but fully integrating it into existing and future care pathways. “Why don’t care programs for diabetes or renal insufficiency automatically include complete smoking cessation treatment, and not just stating an intention to quit?” he asks.

In high-risk situations (after a heart attack, serious chronic conditions, psychiatric disorders), quitting smoking is a medical priority and not an additional option. “When I treat kidney failure, quitting smoking is not a luxury, but a central part of the treatment,” the doctor emphasizes. Including smoking cessation in the care pathway, he said, would ensure better therapeutic consistency, structured follow-up and fairer access to treatments.

Pending a reform that finally brings prevention objectives into line with the concrete resources allocated to patients, healthcare providers continue to struggle with a paradoxical system. “We ask the most vulnerable for enormous willpower, without giving them the financial resources to support it,” summarizes Dr. Nys. An inconsistency that has a high price in practice.